Disease · MONDO_0021055
classic familial adenomatous polyposis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. classic familial adenomatous polyposis. Diseases, record MONDO_0021055. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021055
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
APC - adenomatous polyposis coli, FAP, Familial Adenomatous Polyposis, adenomatous polyposis coli, adenomatous polyposis of the colon, classic FAP, colorectal adenomatous polyposis, familial adenomatous polyposis coli, familial adenomatous polyposis syndrome, familial polyposis, familial polyposis coli, hereditary adenomatous polyposis coli, polyposis coli
- Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CELECOXIB | CHEMBL118 | Small molecule | Approval | DailyMed | 5 | 2 | 2 | Drugs and targets |
| SIROLIMUS | CHEMBL413 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EFLORNITHINE | CHEMBL830 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 3 | 1 | 1 | Drugs and targets |
| SULINDAC | CHEMBL15770 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 3 | 1 | 1 | Drugs and targets |
| ICOSAPENT | CHEMBL460026 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ROFECOXIB | CHEMBL122 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ERLOTINIB HYDROCHLORIDE | CHEMBL1079742 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OBETICHOLIC ACID | CHEMBL566315 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAK-733 | CHEMBL1615025 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GUSELKUMAB | CHEMBL2364648 | Antibody | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS2 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 1 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IL12B | Interleukin-23 | 1 | Interleukin-23 inhibitor | Phase 1 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 1 | Interleukin-23 inhibitor | Phase 1 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 1 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5604 | Drugs and targets |
| MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 | 1 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5605 | Drugs and targets |
| NR1H4 | Bile acid receptor | 1 | Bile acid receptor FXR agonist | Phase 2 | https://conductscience.org/library/genes/9971 | Drugs and targets |
| ODC1 | Ornithine decarboxylase | 1 | Ornithine decarboxylase inhibitor | Phase 3 | https://conductscience.org/library/genes/4953 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
Trials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00151476 | Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients | 68 | 2010-03-04 | Familial Adenomatous Polyposis (FAP) | CELECOXIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00503035 | Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers | Phase 2 | 51 | 2023-02-13 | Familial Adenomatous Polyposis | CELECOXIB | Its record names the disease | ClinicalTrials.gov |
| NCT02961374 | Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer | Phase 2 | 46 | 2021-09-22 | Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis | ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00927485 | Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) | Not applicable | 44 | 2020-12-16 | Familial Adenomatous Polyposis | CURCUMIN | Its record names the disease | ClinicalTrials.gov |
| NCT03095703 | Sirolimus and Familial Adenomatous Polyposis (FAP) | Phase 2 | 4 | 2024-10-24 | Adenomatous Polyposis Coli | SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT06950385 | Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | Phase 3 | 168 | Familial Adenomatous Polyposis (FAP) | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT03649971 | A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | Phase 1 | 77 | Adenomatous Polyposis Coli | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05552755 | Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Phase 1/2 | 67 | Familial Adenomatous Polyposis | TAK-733 | Its record names the disease | ClinicalTrials.gov | |
| NCT00844727 | Coxib-inhibition of Duodenal Polyp Growth in FAP | Phase 2/3 | 38 | Duodenal Polyposis | ROFECOXIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06308445 | Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis | Phase 2 | 25 | Familial Adenomatous Polyposis | SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Curcumin vs Placebo: serious adverse events | 0 of 21 | 0 of 23 | 44 | NCT00927485 |
Source Trial comparisons
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021055
GET https://conductscience.org/api/diseases/v1/MONDO_0021055/drugs